Wei JI Wei, reported drug price negotiations result hepatitis b drug prices

Beijing, May 20, according to the National Health Commission's Web site, the State Health Commission published on 20th the first national drug price negotiations, including first-line treatment for chronic hepatitis b drug tenofovir disoproxil, targeted therapy for non-small cell lung cancer drug IKE for dasatinib and gefitinib. Compared with the public hospitals before the purchase price, 3 kinds of negotiating drug prices fell by over 50%.
Health Planning Commission pointed out that, on patent medicines, exclusive production of drugs, establishing open and transparent, participatory and drug price negotiation mechanism, is to deepen the reform of medical care and promote the public hospital drug centralized purchasing and reduce the burden on patients of important initiatives. On May 20, 2016, the national drug price negotiation results announced to the public, including first-line treatment for chronic hepatitis b drug tenofovir disoproxil, targeted therapy for non-small cell lung cancer drug IKE for dasatinib and gefitinib. Compared with the public hospitals before the purchase price, 3 kinds of negotiating drug prices fell by over 50%, and neighboring countries (regions) convergence.
October 2015, approved by the State Council, 16 ministries such as health and family planning (bureaus) of drug price negotiation is established the Inter-Ministerial Joint Conference system experts a comprehensive patent medicine, exclusive domestic production of drugs, combined with the medication needs of our major public health and disease control, drug selection determines the first negotiations, set up a negotiating team, developing negotiation processes and policies, synchronous negotiation and oversight mechanisms.
In late November, officially launched the first national drug price negotiations. Negotiating teams met with hepatitis b, non-small cell lung cancer with patented medicines-related companies have held several rounds of talks. In this process, departments emphasize policy work together, cooperate closely to advance negotiations. Cooperation enterprises with a positive attitude and a strong sense of social responsibility, to achieve a shared win-win negotiation efforts of the results.
Wei JI Wei said, currently, hepatitis remains one of our major communicable disease control key, heavy disease burden. Tenofovir disoproxil for the treatment of chronic hepatitis b patients with indications of extensive, has a good safety in pregnant women, and can be used for a variety of drug resistance in patients with chronic hepatitis b treatment.
For the class of targeted drugs can conform to the indication of treatment of patients with non-small cell lung cancer with accuracy increase, lifetime extension. Talks pilot started well, made significant progress and results, improve liver, lung cancer patients accessibility and affordability, and masses are the biggest beneficiaries. This has fully demonstrated the Party Central Committee and the State Council on the establishment of the national drug price negotiation mechanism of decision making is entirely correct.
Wei JI Wei emphasized that guidance to implement the outcome of the negotiations as soon as possible to benefit patients, 7 departments jointly issued the negotiations on the national drug procurement notice. Throughout the negotiations in a timely manner results in provincial drug centralized purchasing platform, open mesh, medical institutions by negotiating prices purchasing directly on-line, to improve the scope of Medicare payment management, national pilot drug negotiations and Medicare payment policies, to enhance people's sense of identity and access.
(Editors: Dou Yuan UN833)
2016-05-20 13:26:30
China News Network

卫计委公布药品价格谈判结果 乙肝治疗药物大降价


　　中新网5月20日电  据国家卫生计生委网站消息，国家卫生计生委20日公布首批国家药品价格谈判结果，其中有慢性乙肝一线治疗药物替诺福韦酯，非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。与之前公立医院的采购价格比较，3种谈判药品价格降幅均在50%以上。

　　卫计委指出，对专利药品、独家生产药品，建立公开透明、多方参与的药品价格谈判机制，是深化医药卫生体制改革、推进公立医院药品集中采购、降低广大患者用药负担的重要举措。2016年5月20日，首批国家药品价格谈判结果向社会公布，其中有慢性乙肝一线治疗药物替诺福韦酯，非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。与之前公立医院的采购价格比较，3种谈判药品价格降幅均在50%以上，与周边国家(地区)趋同。

　　2015年10月，经国务院批准，卫生计生等16个部委(局)建立了药品价格谈判部际联席会议制度，组织专家全面梳理国内专利药品、独家生产药品状况，结合我国重大公共卫生和疾病防治的用药需求，遴选确定首批谈判药品，成立谈判小组，制定谈判流程和策略，同步建立谈判和监督工作机制。

　　11月下旬，正式启动首批国家药品价格谈判。谈判小组先后与乙肝、非小细胞肺癌专利药品相关企业进行了多轮谈判。在此过程中，注重发挥部门政策合力，密切配合，共同推进谈判工作。相关企业以积极的合作态度和较强的社会责任感，为达成共享多赢的谈判结果做出了努力。

　　卫计委称，目前，病毒性肝炎仍是我国重大传染病防治重点之一，疾病负担较重。替诺福韦酯对于慢性乙肝患者的治疗适应证广泛，对妊娠期妇女具有很好的安全性，且可用于各种耐药的慢性乙肝患者的治疗。

　　替尼类靶向药物可使符合适应症的非小细胞肺癌患者治疗的精准性提高、生存期延长。谈判试点开局良好，取得重要进展和结果，提高了乙肝、肺癌患者用药的可及性和可负担性，人民群众是最大受益者。这充分证明了党中央、国务院关于建立国家药品价格谈判机制的决策是完全正确的。

　　卫计委强调，为指导各地抓紧落实谈判结果，尽快惠及广大患者，7部门联合印发《关于做好国家谈判药品集中采购的通知》。各地要及时将谈判结果在省级药品集中采购平台上公开挂网，医疗机构按谈判价格直接网上采购，要完善医保支付范围管理办法，做好国家药品谈判试点与医保支付政策衔接，切实增强人民群众的认同感、获得感。
(责任编辑：窦远行 UN833)
2016-05-20 13:26:30
中国新闻网